• Investor returns expected via asset monetization (licensing, JV, M&A, trade sale) or security trading in private/public markets

• Focused on high-burden conditions with limited or no effective pharmacotherapies

• Differentiation supported by peer-reviewed science, clinical and human tissue data, and a portfolio spanning AMPAkines, GABAkines, and a proprietary dronabinol formulation

• Non-dilutive support (grants, Australian R&D incentives) helps offset development risk and capital intensity

• Compelling statistically significant human safety and efficacy established for Ampakines (CX717, CX1739) with more than 250 human subjects and dronabinol, enabling further Phase II/III clinical development for SCI, ADHD and OSA

• Preclinical scientific validation includes multiple animal models in SCI and epilepsy

• Team includes experienced biotech founders, and seasoned CNS drug developers

• Strategy: RespireRx intends to monetize programs via licensing, JVs, asset sales, or M&A rather than direct commercialization; value increases as assets advance through preclinical and clinical milestones

• Partner Economics: Typical structures include upfront payments, milestone payments, and royalties (or profit share in JVs), with development costs borne or shared by partners

• ResolutionRx: Late-stage program with PK/PD study followed by one Phase 3 with proprietary dronabinol formulation for obstructive sleep apnea (large poorly met need); pursuing 505(b)(2) pathway; plan to out-license/JV/sell. Leveraging research and development tax incentive in Australia (43.5%)

• EndeavourRx – AMPAkines:
  • CX1739 – Mid-stage for spinal cord injury (bladder function); DoD-funded Phase 2A/B via trial at Shirley Ryan AbilityLab (~$1.8M grant)
  • CX717 – Phase 2B for ADHD; ~$2.8M NIH grant pending or investor funding

• EndeavourRx – GABAkines: Preclinical program for treatment-resistant epilepsy; ~$3M NIH grant awarded to fund preclinical toxicology program; Phase 1 safety studies planned

*Future targeted program.

Dr. Arnold S. Lippa

Executive Chairman, CEO, CSO

• Founder and CEO of DOV Pharmaceuticals (IPO in 2002)
• 50+ years in neuropharma R&D and venture creation
• Inventor on numerous patents, author of peer-reviewed publications
• A prolific inventor with numerous patents in the medical arena and an author or co-author of numerous peer-reviewed scientific publications

Jeff E. Margolis

SVP, CFO, Board Member

• Founder of Aurora Capital LLC (former FINRA-member firm)
• 30+ years in biotech capital markets
• Co-founder of life sciences investment entity with Dr. Lippa

Richard Purcell

SVP R&D

• 40 years of clinical development and commercialization experience
• Former EVP of NuGenerex Immuno-Oncology
• Active advisor and professor; led biotech/MedTech startups and M&A strategy

Senior Research Fellows

Dr. Jeffrey Witkin, PhD

Ex-Lilly; >250 publications; co-founder Gilgamesh Pharma; lead on GABAkines

Rok Cerne, MD, PhD

Senior Research Fellow 30+ years CNS R&D; key role in analgesic/antiepileptic drug discovery; principal instigator on GABAkines grant application

Daniel Radin, MD, PhD

Group Leader – AMPAKines